Slideshow Preferred Stock Offerings

By Preferred Stock Channel Staff, updated Sat, April 1, 5:06 PM

Slide #162. Ovid Therapeutics Inc. Preferred Stock Offering

Company: Ovid Therapeutics Inc. (NASDAQ:OVID)
Date announced: 2/19/2019
Shares Offered: 2,500
Date of Pricing: 2/20/2019
Price Per Share: $2,000.00
Preferred Stock Offering Details: Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it intends to offer and sell shares of its common stock and Series A convertible preferred stock ("Series A stock") in two concurrent but separate underwritten public offerings. Neither of the proposed common stock offering or the Series A stock offering (together, the "Offerings") are contingent upon the consummation of the other. The Offerings are subject to market and other conditions, and there can be no assurance as to whether or when the Offerings may be completed, or the actual size or terms of the Offerings. -updated 2/20- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the pricing of underwritten public offerings of (i) 12,500,000 shares of its common stock and (ii) 2,500 shares of its non-voting Series A Convertible Preferred Stock ("Series A stock") (together, the "Offerings"). The public offering price of each share of common stock is $2.00 and the public offering price of each share of Series A stock is $2,000.00. In addition, Ovid Therapeutics has granted the underwriters a 30-day option to purchase additional shares of common stock of up to 15% of the number of shares offered in the common stock offering. The Offerings are expected to close on February 22, 2019, subject to customary closing conditions.

Ovid Therapeutics is a biopharmaceutical company focus on reducing seizures and epilepsies and seizure-related neurological disorders. Co.'s pipeline has produced two epilepsy programs with potential mechanisms of action (MoA), and one epilepsy program with a potential MoA. These programs include soticlestat, which is a cholesterol 24 hydroxylase inhibitor. OV350 is a potential direct activator of the K-Cl co-transporter (KCC2) transporter, and is one among many KCC2 activator compounds in its portfolio. OV329 is a GABA aminotransferase inhibitor. Co.'s genetic research programs include OV815, which focuses on the mutations associated with KIF1A-associated neurological disorder.
Open the OVID Page at Preferred Stock Channel »

Ovid Therapeutics Inc
Drugs & Pharmaceuticals
Number of ETFs Holding OVID: 
4 (see which ones)
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the OVID Page at Preferred Stock Channel (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree OVID Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Strong Buy (3.50 out of 4)
59th percentile
(ranked higher than approx. 59% of all stocks covered)
Based on data provided by Zacks Investment Research via
Top Ten Highest Yielding Preferred Stocks
Feel-Good Income: Socially Responsible Preferreds
Dividend Channel's 25 S.A.F.E. Dividend Stocks
Increasing Payments For Decades

Safer than S.A.F.E: Preferreds of Dividend Channel's
S.A.F.E. Dividend Stocks

Recent Preferred Stock Offerings
Preferred Stocks of Dow Components
Preferred Stocks of S&P 500 Components
Preferred Stocks By Industry
Preferred Stocks Where Insiders Are Buying The Common
High Yield Preferred Stocks
Preferreds Trading At Premiums To Liquidation Preference
Preferreds Trading At Discounts To Liquidation Preference
The Top 10 DividendRank'ed U.S. Stocks
The Top 10 DividendRank'ed Canadian Stocks
Top 25 Broker Analyst Picks of the S&P 500
Stock market game

Preferred Stock Offerings - Slide 162 of 609 |

Copyright © 2010 - 2023, All Rights Reserved Nothing in Preferred Stock Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Preferred Stock Channel; Meet Our Editorial Staff.